74
A. Holtfrerich et al. / European Journal of Medicinal Chemistry 63 (2013) 64e75
[20] K. Schoenafinger, S. Petry, G. Mueller, A. Bauer, H.O. Heuer, Use of Substituted
3-Phenyl-5-Alkoxy,1,3,4-Oxdiazole-2-One for Producing Medicaments that
Inhibit Pancreatic Lipase. WO03072098 (2003).
[21] Y.M. Shen, M. Shi, Transition-metal-catalyzed reactions of 5-methylene-2-
oxazolidinone and 5-methylene-1,3-thiazolidine-2-thione with isocyanates,
Appl. Organomet. Chem. 17 (2003) 767e775.
a Waters column oven and a Waters UV/vis-detector model 2487.
Instrument control, data collection, and processing were handled
by Waters Millenium32 Chromatography Software.
Separation was achieved on a Kromasil C18 analytical column
(3 mm inside diameter ꢂ 125 mm, particle size 3
with a Phenomenex C18 guard column (3 mm inside diame-
L of each sample were injected onto the HPLC
mm) protected
[22] M. Hess, A. Schulze Elfringhoff, M. Lehr, 1-(5-Carboxy- and 5-carbamoylindol-
1-yl)propan-2-ones as inhibitors of human cytosolic phospholipase
A2a:
bioisosteric replacement of the carboxylic acid and carboxamide moiety,
Bioorg. Med. Chem. 15 (2007) 2883e2891.
ter ꢂ 4 mm). 50
m
system. The temperature of the autosampler was kept at 10 ꢀC, the
column oven was maintained at 20 ꢀC. As mobile phase a mixture of
acetonitrile/water/concentrated phosphoric acid (85%) was used.
Depending on the lipophilicity of the test compounds, the com-
position of the mobile phase ranged from 70/30/0.1 to 85/15/0.1 (v/
v/v). The flow rate was 0.4 mL/min. The effluents were monitored at
240 nm. The rate of metabolism was calculated from the peak area
of the parent compound measured in the metabolism sample and
the peak area of this substance obtained with the blank solution.
[23] L. Boukli, M. Touaibia, N. Meddad-Belhabich, A. Djimdé, C.H. Park, J.J. Kim,
J.H. Yoon, A. Lamouri, F. Heymans, Design of new potent and selective
secretory phospholipase A2 inhibitors. Part 5: synthesis and biological activity
of
1-alkyl-4-[4,5-dihydro-1,2,4-[4H]-oxadiazol-5-one-3-ylmethylbenz-40-
yl(oyl)] piperazines, Bioorg. Med. Chem. 16 (2008) 1242e1253.
[24] G. Bruno, L. Costantino, C. Curinga, R. Maccari, F. Monforte, F. Nicolo, R. Ottana,
M.G. Vigorita, Synthesis and aldose reductase inhibitory activity of 5-
arylidene-2,4-thiazolidinediones, Bioorg. Med. Chem. 10 (2002) 1077e1084.
[25] F. Li, Q. Meng, H. Chen, Z. Li, Q. Wang, F. Tao, Synthesis of diaryl ethers, diaryl
sulfides, heteroaryl ethers and heteroaryl sulfides under microwave dielectric
heating, Synthesis 8 (2005) 1305e1313.
[26] H. Barth, K. Steiner, H.J. Betche, S. Schneider, U. Bayer, M. Westermeyer,
U. Wolfsperger, Verfahren zur Arylierung von Aza-Heterozyklen mit akti-
vierten Aromaten in Gegenwart von Caesiumcarbonat. WO 0059883 (2000).
[27] A. Gangjee, J. Patel, R.L. Kisliuk, Y. Gaumont, 5,10-Methylenetetrahydro-5-
deazafolic acid and analogues: synthesis and biological activities, J. Med.
Chem. 35 (1992) 3678e3685.
[28] R. Rips, N.P. Buu-Hoi, Friedel-Crafts acylations of 1-phenyl-2,5-dimethylpyrrole
and 1,2-diphenyl-5-methylpyrrole, J. Org. Chem. 124 (1959) 551e554.
[29] M. Rusch, S. Zahov, I. Vetter, M. Lehr, C. Hedberg, Design, synthesis and
evaluation of polar head group 2-keto-oxazole inhibitors of fatty acid amide
hydrolase (FAAH), Bioorg. Med. Chem. 20 (2012) 1100e1112.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
References
[30] A. Holtfrerich, T. Makharadze, M. Lehr, High-performance liquid chromatog-
raphy assay with fluorescence detection for the evaluation of inhibitors
against human recombinant monoacylglycerol lipase, Anal. Biochem. 399
(2010) 218e224.
[31] L. Forster, A. Schulze Elfringhoff, M. Lehr, High-performance liquid chromato-
graphic assay with fluorescence detection for the evaluation of inhibitors
against fatty acid amide hydrolyse, Anal. Bioanal. Chem. 394 (2009) 1679e1685.
[32] J.A. Crow, V. Bittles, A. Borazjani, P.M. Potter, M.K. Ross, Covalent inhibition of
recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by
thecarbamatesJZL184andURB597, Biochem.Pharmacol. 84(2012)1215e1222.
[33] B. Paylor, S. Holt, C.J. Fowler, The potency of the fatty acid amide hydrolyse
inhibitor URB597 is dependent upon the assay pH, Pharmacol. Res. 54 (2006)
481e485.
[1] G. Labar, C. Michaux, Fatty acid amide hydrolase: from characterization to
therapeutics, Chem. Biodiversity 4 (2007) 1882e1902.
[2] S.M. Saario, J.T. Laitinen, Monoglyceride lipase as an enzyme hydrolyzing 2-
arachidonoylglycerol, Chem. Biodiversity 4 (2007) 1903e1913.
[3] S.M. Saario, J.T. Laitinen, Therapeutic potential of endocannabinoid-hydrolysing
enzyme inhibitors, Basic Clin. Pharmacol. Toxicol. 101 (2007) 287e293.
[4] J.E. Schlosburg, S.G. Kinsey, A.H. Lichtman, Targeting fatty acid amide hydro-
lase (FAAH) to treat pain and inflammation, AAPS J. 11 (2009) 39e44.
[5] J.Z. Long, W. Li, L. Booker, J.J. Burston, S.G. Kinsey, J.E. Schlosburg, F.J. Pavón,
A.M. Serrano, D.E. Selley, L.H. Parsons, A.H. Lichtman, B.F. Cravatt, Selective
blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behav-
ioral effects, Nat. Chem. Biol. 5 (2009) 37e44.
[34] S. Kathuria, S. Gaetani, D. Fegley, F. Valino, A. Duranti, A. Tontini, M. Mor,
G. Tarzia, G. La Rana, A. Calignano, A. Giustino, M. Tattoli, M. Palmery,
V. Cuomo, D. Piomelli, Modulation of anxiety through blockade of ananda-
mide hydrolysis, Nat. Med. 9 (2003) 76e81.
[35] S.M. Saario, A. Poso, R.O. Juvonen, T. Järvinen, O.M. Salo-Ahen, Fatty acid
amide hydrolase inhibitors from virtual screening of the endocannabinoid
system, J. Med. Chem. 49 (2006) 4650e4656.
[36] A.K. Dickason-Chesterfield, S.R. Kidd, S.A. Moor, J.M. Schaus, B. Liu,
G.G. Nomikos, C.C. Felder, Pharmacological characterization of endocannabi-
noid transport and fatty acid amide hydrolase inhibitors, Cell. Mol. Neurobiol.
26 (2006) 407e423.
[37] K. Ahn, D.S. Johnson, L.R. Fitzgerald, M. Liimatta, A. Arendse, T. Stevenson,
E.T. Lund, R.A. Nugent, T.K. Nomanbhoy, J.P. Alexander, B.F. Cravatt, Novel
mechanistic class of fatty acid amide hydrolase inhibitors with remarkable
selectivity, Biochemistry 46 (2007) 13019e13030.
[38] M.K. Ramarao, E.A. Murphy, M.W. Shen, Y. Wang, K.N. Bushell, N. Huang,
N. Pan, C. Williams, J.D. Clark, A fluorescence-based assay for fatty acid amide
hydrolase compatible with high-throughput screening, Anal. Biochem. 343
(2005) 143e151.
[39] D. Leung, C. Hardouin, D.L. Boger, B.F. Cravatt, Discovering potent and selec-
tive reversible inhibitors of enzymes in complex proteomes, Nat. Biotechnol.
21 (2003) 687e691.
[40] G.G. Mucciol, G. Labar, D.M. Lambert, CAY10499, a novel monoglyceride lipase
inhibitor evidenced by an expeditious MGL assay, ChemBioChem 9 (2008)
2704e2710.
[41] J.Z. Long, D.K. Nomura, B.F. Cravatt, Characterization of monoacylglycerol
lipase inhibition reveals differences in central and peripheral endocannabi-
noid metabolism, Chem. Biol. 16 (2009) 744e753.
[6] S. Vandevoorde, Overview of the chemical families of fatty acid amide hy-
drolase and monoacylglycerol lipase inhibitors, Curr. Top. Med. Chem. 8
(2008) 247e267.
[7] M. Seierstad, J.G. Breitenbucher, Discovery and development of fatty acid
amide hydrolase (FAAH) inhibitors, J. Med. Chem. 51 (2008) 7327e7343.
[8] J.A. Cisneros, E. Björklund, I. Gonzalez-Gil, Y. Hu, A. Canales, F.J. Medrano,
A. Romero, S. Ortega-Gutierrez, C.J. Fowler, M.L. Lopez-Rodriguez, Structuree
activity relationship of a new series of reversible dual monoacylglycerol lipase/
fatty acid amide hydrolase inhibitors, J. Med. Chem. 55 (2012) 824e836.
[9] J.Z. Long, X. Jin, A. Adibekian, W. Li, B.F. Cravett, Characterization of tunable
piperidine and piperazine carbamates as inhibitors of endocannabinoid hy-
drolases, J. Med. Chem. 53 (2010) 1830e1842.
[10] L. Morera, G. Labar, G. Ortar, D.M. Lambert, Development and characterization
of endocannabinoid hydrolases FAAH and MAGL inhibitors bearing a benzo-
triazol-1-yl carboxamide scaffold, Bioorg. Med. Chem. 20 (2012) 6260e6275.
[11] A. Viso, J.A. Cisneros, S. Ortega-Gutiérrez, The medicinal chemistry of agents
targeting monoacylglycerol lipase, Curr. Top. Med. Chem. 8 (2008) 231e246.
[12] A. Minkkilä, J.R. Savinainen, H. Käsnänen, H. Xhaard, T. Nevalainen,
J.T. Laitinen, A. Poso, J. Leppänen, S.M. Saario, Screening of various hormone-
sensitive lipase inhibitors as endocannabinoid-hydrolyzing enzyme in-
hibitors, ChemMedChem 4 (2009) 1253e1259.
[13] T. Yamashita, H. Nara, M. Takizawa, K. Yoshimura, Thiol Compounds, Their
Production and Use, US6420415 (2002).
[14] C.M. Martinez-Viturro, D. Dominguez, Synthesis of aza analogues of the
anticancer agent batracylin, Tetrahedron Lett. 48 (2007) 4707e4710.
[15] W.E. Noland, N.P. Lanzatella, L. Venkatraman, N.F. Anderson, G.C. Gullickson,
Access to indoles via DielseAlder reactions of 2-vinylpyrroles with mal-
eimides, J. Heterocycl. Chem. 46 (2009) 1154e1176.
[42] M. Johnston, S.R. Bhatt, S. Sikka, R.W. Mercier, J.M. West, A. Makriyannis,
S.J. Gatley, R.I. Duclos, Assay and inhibition of diacylglycerol lipase activity,
Bioorg. Med. Chem. Lett. 22 (2012) 4585e4592.
[43] J.R. Savinainen, M. Yoshino, A. Minkkilä, T. Nevalainen, J.T. Laitinen, Charac-
terization of binding properties of monoglyceride lipase inhibitors by a ver-
satile fluorescence-based technique, Anal. Biochem. 399 (2010) 132e134.
[44] W. Marrs, N. Stella, Measuring endocannabinoid hydrolysis: refining our tools
and understanding, AAPS J. 11 (2009) 307e311.
[45] R. Homan, K.L. Hamelehe, Influence of membrane partitioning on inhibitors of
membrane-bound enzymes, J. Pharm. Sci. 90 (2001) 1859e1867.
[46] S.M. Saario, O.M. Salo, T. Nevalainen, A. Poso, J.T. Laitinen, T. Järvinen, R. Niemi,
Characterization of the sulfhydryl-sensitive site in the enzyme responsible for
[16] J.M. Hill, G. Yu, Y.K. Shue, T.M. Zydowsky, J. Rebek, Aminoacyl Adenylate
Mimics as Novel Antimicrobial and Antiparasitic Agents, US5726195 (1998).
[17] G. Ortar, M.G. Cascio, A.S. Moriello, M. Camalli, E. Morera, M. Nalli, V. Di Marzo,
Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: a critical
revisitation, Eur. J. Med. Chem. 243 (2008) 62e72.
[18] S. Kobayashi, Y. Tsuchiya, T. Mukaiyama, A facile synthesis of cyanohydrin
trimethylsilyl ethers by the addition reaction of trimethylsilyl cyanide with
aldehydes under basic condition, Chem. Lett. 20 (1991) 537e540.
[19] K. Dewkar, S. Peddi, P.D. Mosier, B.L. Roth, R.B. Westkaemper, Methoxy-
substituted 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives
exhibit differential binding affinities at the 5-HT2A receptor, Bioorg. Med.
Chem. Lett. 18 (2008) 5268e5271.